Literature DB >> 1385412

Heparin-binding properties of vitronectin are linked to complex formation as illustrated by in vitro polymerization and binding to the terminal complement complex.

K Høgåsen1, T E Mollnes, M Harboe.   

Abstract

Vitronectin (VN, complement S-protein) is a multifunctional protein which participates in cell adhesion, coagulation, fibrinolysis, and protection against complement lysis. VN is incorporated into several complexes, such as the terminal complement complex and thrombin-antithrombin III, and is bound to plasminogen activator inhibitor 1. The present study showed that purified VN spontaneously forms polymers of approximately 1000 kDa with a Stokes radius of 10 nm. The polymers are to a varying extent stabilized by disulfide bonds, but are quite stable even after reduction and alkylation, indicating the importance of noncovalent bonds. Plasma VN circulates mainly as a 65/75-kDa monomer containing a cryptic heparin-binding site which is exposed upon a conformational change induced by different stimuli, such as coagulation, heating, adsorption to surfaces, or exposure to acids, urea, or other denaturating agents. In the present study, VN was demonstrated to expose its heparin-binding site and its conformationally dependent 8E6 epitope when incorporated into the terminal complement complex. We suggest that exposure of the heparin-binding site and a putative hydrophobic binding site of VN are linked events dependent upon the same conformational change. In vivo, complex formation probably induces the heparin-binding site. Such a link might also explain why purified heparin-binding VN spontaneously forms polymers. The heparin-binding site may be involved in the elimination of multimolecular complexes containing VN.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1385412

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Drusen proteome analysis: an approach to the etiology of age-related macular degeneration.

Authors:  John W Crabb; Masaru Miyagi; Xiaorong Gu; Karen Shadrach; Karen A West; Hirokazu Sakaguchi; Motohiro Kamei; Azeem Hasan; Lin Yan; Mary E Rayborn; Robert G Salomon; Joe G Hollyfield
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-21       Impact factor: 11.205

Review 2.  Complement activation in the context of stem cells and tissue repair.

Authors:  Ingrid U Schraufstatter; Sophia K Khaldoyanidi; Richard G DiScipio
Journal:  World J Stem Cells       Date:  2015-09-26       Impact factor: 5.326

3.  Presence of plasma complement regulatory proteins clusterin (Apo J) and vitronectin (S40) on circulating immune complexes (CIC).

Authors:  A K Chauhan; T L Moore
Journal:  Clin Exp Immunol       Date:  2006-09       Impact factor: 4.330

4.  Immunological Aspects of Age-Related Macular Degeneration.

Authors:  Michael J Allingham; Anna Loksztejn; Scott W Cousins; Priyatham S Mettu
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Complement inhibition by human vitronectin involves non-heparin binding domains.

Authors:  M Sheehan; C A Morris; B A Pussell; J A Charlesworth
Journal:  Clin Exp Immunol       Date:  1995-07       Impact factor: 4.330

6.  The kinetics and distribution of C9 and SC5b-9 in vivo: effects of complement activation.

Authors:  J D Greenstein; P W Peake; J A Charlesworth
Journal:  Clin Exp Immunol       Date:  1995-04       Impact factor: 4.330

7.  Extensive complement activation in hereditary porcine membranoproliferative glomerulonephritis type II (porcine dense deposit disease).

Authors:  J H Jansen; K Høgåsen; T E Mollnes
Journal:  Am J Pathol       Date:  1993-11       Impact factor: 4.307

8.  New insights into heparin binding to vitronectin: studies with monoclonal antibodies.

Authors:  P Anne Underwood; Alan Kirkpatrick; Sue M Mitchell
Journal:  Biochem J       Date:  2002-07-01       Impact factor: 3.857

9.  Low levels of vitronectin and clusterin in acute meningococcal disease are closely associated with formation of the terminal-complement complex and the vitronectin-thrombin-antithrombin complex.

Authors:  K Høgåsen; T E Mollnes; P Brandtzaeg
Journal:  Infect Immun       Date:  1994-11       Impact factor: 3.441

10.  Formation of soluble amyloid oligomers and amyloid fibrils by the multifunctional protein vitronectin.

Authors:  Thuzar M Shin; J Mario Isas; Chia-Ling Hsieh; Rakez Kayed; Charles G Glabe; Ralf Langen; Jeannie Chen
Journal:  Mol Neurodegener       Date:  2008-10-21       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.